Cognitive Benefits of Aerobic Exercise Across the Age Span



Status:Completed
Conditions:Cognitive Studies
Therapuetic Areas:Psychiatry / Psychology
Healthy:No
Age Range:20 - 68
Updated:8/19/2018
Start Date:August 2010
End Date:June 29, 2016

Use our guide to learn which trials are right for you!

The purpose of this study is to test the hypothesis that aerobic exercise leads improved
cognitive function accompanied by increases in gray matter density and changes in functional
magnetic resonance imaging (fMRI) patterns of task-related activation.

While animal and human studies indicate cognitive benefits from aerobic exercise across the
lifespan, the great majority of controlled exercise studies in humans have been restricted to
elderly individuals. Those studies have indicated that enhancing aerobic capacity has a
beneficial effect on cognition. One study suggests that this benefit is seen particularly for
executive control processes, precisely the processes affected by aging. These improvements
have been accompanied by increases in gray matter density and changes in functional magnetic
resonance imaging (fMRI) patterns of task-related activation. The goal of the proposed study
is to extend the investigation of the beneficial effects of aerobic exercise to younger
individuals, and to compare these effects in young and old.

In this application the study team propose to conduct a study in which 270 sedentary but
otherwise healthy and cognitively intact individuals in the 20-68 year age range are
randomized to two training conditions, aerobic exercise and stretching/toning, to be
completed at YMCAs and YMHAs in New York City. Participants will be assessed for aerobic
capacity, cognitive task performance, and by structural MRI, resting cerebral blood flow
scans (arterial spin labeling) and cognitive activation fMRI studies at study entry and after
6 months of training.

The study also proposes two complementary approaches to investigating the neural correlates
of the beneficial effects of aerobic exercise on cognition: 1) imaging -- a combination of
structural, metabolic, and cognitive activation fMRI studies to evaluate the neural
substrates of the effect of aerobic exercise on cognition will be used. 2) important
correlates -- the effects of apolipoprotein E (APOE) genotype, inflammatory markers and
cognitive reserve on the cognitive effects of aerobic exercise will be explored.

Inclusion Criteria:

1. Age 20-68

2. English-speaking

3. strongly right-handed

4. BMI < 35

5. Pre-menopausal (women only): no oral contraceptive use Post-menopausal: no estrogen
replacement therapy

6. sedentary: VO2 max < 41 and 31.6 ml/kg/min for men age 20-40 and 50-68 and < 35.2 and
26.6 ml/kg/min for women age 20-40 and 50-68 respectively

7. participants over age 60 must have ECG within past 3 months

Exclusion Criteria:

1. MRI contraindications (e.g., metallic implants, pacemaker, weight > 350 lbs, waist >
55")

2. Hearing impaired/hearing aids, unable to read newspaper at arm's length with
corrective lenses

3. Objective cognitive impairment

4. Ischemic changes, abnormal blood pressure responses, or any significant ectopy during
aerobic capacity testing

5. Cardiovascular disease

6. Uncontrolled high blood pressure (systolic blood pressure ≥ 140 mmHg; or diastolic
blood pressure ≥ 90 mmHg on two measures)

7. Current or recent (evidence of disease x 5 years) non-skin neoplastic disease or
melanoma

8. Active hepatic disease (not a history of hepatitis) or primary renal disease requiring
dialysis, primary untreated endocrine diseases, e.g., Cushing's disease or primary
hypothalamic failure or insulin dependent diabetes (Type I or II).

9. HIV infection

10. Pregnant or lactating (participation allowed 3 months after ceasing lactation

11. Medications that target CNS (central nervous system, e.g., neuroleptics,
anticonvulsants, antidepressants, benzodiazepines) within the last month

12. Women: any selective estrogen receptor modulator or aromatase inhibitor Men: androgen
ablation/deprivation hormonal therapies

13. Any history of psychosis or electroconvulsive therapy

14. Psychotic disorder (lifetime)

15. Current or recent (within past 12 months) alcohol or substance abuse or dependence.
Recent use (past month) of recreational drugs.

16. Brain disorder such as stroke, tumor, infection, epilepsy, multiple sclerosis,
degenerative diseases, head injury, mental retardation

17. Imaged cortical stroke or large subcortical lacunae or infarct or space-occupying
lesion (≥ 2 cubic cm). Other findings, e.g., periventricular caps or small white
matter hyperintensities, do not result in exclusion

18. Diagnosed learning disability, dyslexia

19. Current or recent (Past 5 years) Major Depressive Disorder, Bipolar Disorder, or
Anxiety Disorder

20. Dementia Rating Scale < 135
We found this trial at
1
site
New York, New York 10013
?
mi
from
New York, NY
Click here to add this to my saved trials